Absci (ABSI) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
12 Nov, 2026Platform and pipeline
Six-week lab-in-the-loop cycles; discovery estimated at $10–15M and 24 months, versus $50–100M and 5–6 years for large pharma.
Pipeline includes ABS-201 for pattern hair loss and endometriosis, ABS-202 for immunology and inflammation, and early-stage programs available for partnering.
Three clinical-stage programs have been delivered to date; the preclinical pipeline focuses on metabolism and immunology and inflammation.
More than 25 partnered programs to date, with collaboration focus on challenging targets or epitopes, differentiated target product profiles, and mono- or multispecific formats.
ABS-201 in pattern hair loss
Estimated 80M Americans have pattern hair loss: ~50M men and ~30M women; the presentation positions hair regrowth and limited treatment options as key unmet needs.
HEADLINE is a double-blind, placebo-controlled Phase 1/2a trial; all planned SAD cohorts were dosed, and MAD cohorts 1–3 were fully enrolled as of May 31, 2026.
Interim SAD results showed favorable safety across blinded cohorts and a half-life of at least 65 days; PK modeling supports potential for 2–3 injections over six months to maintain >90% receptor occupancy.
A 13-week interim proof-of-concept readout is expected in Dec 2026, with 26-week topline results expected in 2027.
Market research estimates a U.S. TAM >$25B and potential global TAM >$40B; the proposed profile targets infrequent dosing and potentially durable hair growth.
ABS-201 in endometriosis
Endometriosis treatment commonly includes hormonal therapies and surgery; the presentation describes chronic disease, persistent pain, and limitations in existing options.
PRLR antagonism is presented as a non-sex-hormone mechanism with potential effects on both lesion growth and pain; preclinical studies report reduced lesion formation and pain-related measures in mice.
The proposed opportunity addresses 9M U.S. patients, with potential peak sales >$4.5B; the presentation cites HMI-115 Phase 2 as clinical validation of the mechanism.
Phase 2 initiation is expected in mid-2027.
Latest events from Absci
- ABS-201 readouts approach as $173.7M liquidity supports projected runway into H2 2028.ABSI
Q3 2026 - ABS-201 readouts are approaching, with cash runway into H2 2028.ABSI
3rd Annual Guggenheim Healthcare Innovation Conference - ABS-201 advances with strong safety, high demand, and pivotal data expected in December.ABSI
Morgan Stanley 24th Annual Global Healthcare Conference - AI-driven clinical programs advance toward key milestones, supported by robust cash reserves.ABSI
H.C. Wainwright 28th Annual Global Investment Conference - AI-driven antibody platform advances novel therapies for hair loss and endometriosis, targeting large markets.ABSI
Corporate presentation - Positive interim data and strong cash reserves support continued clinical and pipeline progress.ABSI
Q2 2026 - AI-powered drug discovery advances key assets toward pivotal clinical milestones and partnerships.ABSI
Morgan Stanley 23rd Annual Global Healthcare Conference - AI-driven antibody platform advances ABS-101 and ABS-201 toward major clinical milestones.ABSI
R&D Day 2024 - Generative AI-driven antibody design, AMD partnership, and pipeline milestones set stage for 2025.ABSI
43rd Annual J.P. Morgan Healthcare Conference 2025